You can buy or sell Daiichi Sankyo and other stocks, options, ETFs, and crypto commission-free!
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. Read More The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan. DSNKY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).
52 Week High
52 Week Low
FDA advisory panel votes against Daiichi Sankyo's cancer treatment
(Reuters) - Independent experts on an FDA advisory panel on Tuesday voted against Daiichi Sankyo Co Ltd’s treatment for adults with a type of acute myeloid leukemia.
Seeking AlphaMay 13
Daiichi Sankyo launches MINNEBRO tablets in Japan
Exelixis' (NASDAQ:EXEL) partner Daiichi Sankyo (OTCPK:DSNKY) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.
Yahoo FinanceMay 13